These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 38746033)

  • 1. Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.
    Stan SI; Biciuşcă V; Clenciu D; Mitrea A; Boldeanu MV; Durand P; Dănoiu S
    Med Pharm Rep; 2024 Apr; 97(2):111-119. PubMed ID: 38746033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
    Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
    Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
    Kim SG; Kim BK; Kim K; Fang S
    Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease.
    Xiao Y; Kim M; Lazar MA
    Mol Metab; 2021 Aug; 50():101119. PubMed ID: 33220489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting nuclear receptors for the treatment of fatty liver disease.
    Tanaka N; Aoyama T; Kimura S; Gonzalez FJ
    Pharmacol Ther; 2017 Nov; 179():142-157. PubMed ID: 28546081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease.
    Xu Y; An Z; Wang S; Ni Y; Zhou M; Feng Q; Gou X; Xu M; Qi Y
    Curr Mol Pharmacol; 2023 Oct; ():. PubMed ID: 37936450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities and Metabolic Derangement of NAFLD.
    Bang KB; Cho YK
    J Lifestyle Med; 2015 Mar; 5(1):7-13. PubMed ID: 26528424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
    Radwan MM; Radwan BM; Nandipati KC; Hunter WJ; Agrawal DK
    Expert Rev Clin Immunol; 2013 Aug; 9(8):727-38. PubMed ID: 23971751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
    Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
    Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.
    Campbell P; Symonds A; Barritt AS
    Clin Ther; 2021 Mar; 43(3):500-517. PubMed ID: 33583577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.